Aier Eye Hospital Group (300015) Fair Value & Analysis
Healthcare · CN · Market cap 83.8B CNY
Fair value as of: Jul 17, 2026
From 26 valuation models · updated 21 days ago
Fair value updated Jul 17, 2026, revised from ¥7.64 to ¥7.67 (+0.4%) since Jul 7, 2026. Share price +7.1% over the past month.
A solid business, but screening 12% overvalued on our models.
What matters now
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
- Our model range runs from ¥5.75 (bear) to ¥9.58 (bull), base ¥7.67. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 54/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range ¥7.91 – ¥40.07 · fair‑value band ¥5.75 – ¥9.58 · the ¥8.73 price screens above the ¥7.67 fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Aier Eye Hospital Group (300015) currently trades at ¥8.73, while our model-based Fair Value estimate is ¥7.67, implying the stock looks roughly 12.1% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Aier Eye Hospital Group generated revenue of 22.7B CNY at a net margin of 14.8%. Revenue grew 6.1% year over year. It earns a return on equity of 15.2%. Net debt stands at 651M CNY. Fundamentals as of Jul 17, 2026
Our scenario range runs from ¥5.75 (bear case) to ¥9.58 (bull case); at ¥8.73, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -12%, 300015 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥12.29) versus Asset-Based (¥1.58). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Aier Eye Hospital Group Co., Ltd. operates as an ophthalmic medical company in China, Hong Kong, Europe, the United States, Europe, and Southeast Asia. It offers diagnosis and treatment of various ophthalmic diseases, surgical services, medical optometry, and lens fitting for fundus diseases, glaucoma, and cataract.
Full company description
Aier Eye Hospital Group Co., Ltd. operates as an ophthalmic medical company in China, Hong Kong, Europe, the United States, Europe, and Southeast Asia. It offers diagnosis and treatment of various ophthalmic diseases, surgical services, medical optometry, and lens fitting for fundus diseases, glaucoma, and cataract. The company also provides training courses for cataract cases, ICL surgery, and presbyopia surgery. Aier Eye Hospital Group Co., Ltd. was founded in 2002 and is headquartered in Changsha, China
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aier Eye Hospital Group reported revenue of ¥22.4B in FY2025 versus ¥15.0B in FY2021, a compound +10.5%/yr. Reported net income was ¥3.2B in FY2025, compounding +8.7%/yr from FY2021.
300015 screens 12% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,103 | ₹284.87 | -74% |
Compare Aier Eye Hospital Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aier Eye Hospital Group (300015) overvalued or undervalued?
What is the fair value of 300015?
What is the quality score of 300015?
What is the revenue of Aier Eye Hospital Group (300015)?
What is the net profit margin of 300015?
Does Aier Eye Hospital Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Aier Eye Hospital Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.